Amgen said that an injectable version of its eye drug Tepezza succeeded in a Phase 3 study for thyroid eye disease, setting up a showdown

Takeda’s ongoing restructuring has hit another Denali program as an eight-year-old partnership comes to an end between the two companies. Takeda returned the full rights

Neurocrine Biosciences is joining the M&A bonanza with a $2.9 billion takeover of profitable rare disease drugmaker Soleno Therapeutics. Neurocrine will pay $53 per share,

It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for

Syneron Bio said it raised a Series B round worth $150 million, which it will use to back the development of a drug class that’s